Navigation Links
Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012
Date:2/3/2012

DANBURY, Conn., Feb. 3, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2012 financial results on February 8, 2012.  Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress. 

February 8, 2012 schedule: 

 4:00 pm EST:

1Q fiscal year 2012 results will be distributed 

 4:15 pm EST:

Conference call participants should dial: 

+1 ( 877 ) 303 - 8028  (United States) or 

+1 ( 760 ) 536 - 5167  (International) 

  

 4:30 pm EST:

Conference call begins 

  

 Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at www.biodel.com.  The audio webcast will be archived and available for replay through the website.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients.  We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

Contact: Seth D. Lewis, +1-646-378-2952

 

 


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
3. Biodel to Raise $30 Million Through Registered Direct Offering
4. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
5. Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
6. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
7. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
8. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
9. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
10. Par Pharmaceutical Reports Second Quarter 2008 Results
11. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):